ProKidney Corp.: financial analysis
Ratios worked out from 7 fiscal years of ProKidney Corp.'s statements, compared with 665 companies in Biotechnology.
ProKidney Corp. scorecard#
Passes 1 of the 12 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median577.3×Price to sales 577.3× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-30.4%Free cash flow is -30.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$69 M-$69 M in fiscal 2025 against -$27 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$69 MNet income -$69 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities9.1×Current ratio 9.13 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone1.64Z-score 1.64 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- ✗Dividends and buybacks above 3% of the market value0.0%Dividends and buybacks were 0.0% of the market value.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Net loss of $69 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$135 million.
- Shareholders' equity is negative: -$1.0 billion.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseno
- Cash from operations exceeds profitno
- Long-term debt fell against assetsnot on file
- Current ratio roseno
- No new shares issuednot on file
- Gross margin rosenot on file
- Asset turnover roseyes
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.74 | × 1.2 | 0.89 |
| Retained earnings to assets | -3.78 | × 1.4 | -5.30 |
| Operating income to assets | -0.49 | × 3.3 | -1.62 |
| Market value to liabilities | 12.78 | × 0.6 | 7.67 |
| Revenue to assets | 0.00 | × 1 | 0.00 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Return on equity | — | — | — | — | -299.9% | -61.0% | — | |
| Return on assets | -17.8% | -14.2% | -7.6% | -53.1% | -136.9% | -44.4% | 78% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Interest cover | — | — | — | -695.50× | — | -22.77× | — | |
| Current ratio | 9.13× | 10.93× | 14.94× | 46.43× | 2.22× | 4.39× | 76% | |
| Equity share of assets | -301.3% | -225.6% | -262.4% | -211.7% | 66.8% | 64.7% | 3% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $-135 M | $-156 M | $-124 M | $-79 M | $-55 M | $-40 M | 19% |
How each figure is worked out#
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Buyback yield
- Shares bought back in the fiscal year as a share of today's market value.
- Shareholder yield
- Dividends plus buybacks as a share of today's market value.
Source: ProKidney Corp.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 665 companies in Biotechnology that ProKidney Corp. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to ProKidney Corp.